Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Shrinking team NBB
FTE fell two years in a row, from 12.6 to 10.5.
Financials
Financial year 2025
D4-PHARMA from Etterbeek, company number BE0670945535, closed financial year 2025 with a result of € 15,203 after tax. For that financial year D4-PHARMA recorded a gross margin of € 740,002 and equity of € 167,820. Compared with financial year 2024, the result moved from € 85,204 to € 15,203. The company is profitable. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 31, 2026.
€ 167,820
▼ 26% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 15,203
▼ 82% vs 2024
Profit after tax over the fiscal year.
€ 122,742
▲ 99% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 75,000 paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
10.5
▼ 0.9 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 608,551
▲ 4% vs 2024
€ 58,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 34,306
▲ € 29,356 vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 892,286
▲ 195% vs 2024
€ 286,014 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.
€ 498,201
▲ 24% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 90,903
▼ 25% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 598,689 | € 618,767 | € 717,320 | € 740,002 | ▲ 3% |
| Profit after taxes | € -31,596 | € -19,246 | € 85,204 | € 15,203 | ▼ 82% |
| Equity | € 236,659 | € 217,413 | € 227,617 | € 167,820 | ▼ 26% |
| Total debts | € 751,876 | € 770,780 | € 950,311 | € 1,606,615 | ▲ 69% |
| Cash | € 63,692 | € 85,395 | € 61,608 | € 122,742 | ▲ 99% |
| Retained profit | € 216,254 | € 197,008 | € 207,212 | € 147,415 | ▼ 29% |
| Dividend | € 0 | € 0 | € 75,000 | € 75,000 | |
| Bank debt | € 334,683 | € 324,826 | € 301,964 | € 892,286 | ▲ 195% |
| Balance sheet total | € 988,535 | € 988,193 | € 1,177,928 | € 1,774,435 | ▲ 51% |
| Employees (FTE) | 12.2 | 12.6 | 11.4 | 10.5 | ▼ 0.9 |
Key figures of D4-PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to D4-PHARMA?
What happened at D4-PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 15,203 (▼ 82% vs 2024). filed late Source: NBB ↗
- AGANJU HOLDING SRL became a director. NBB
- New establishment in Etterbeek. KBO
- New establishment in Elsene. KBO
- Start of the company according to the CBE. KBO
In short
From € 31,596 loss in 2022 to € 15,203 profit in 2025.
Paid € 9,429 in corporate taxes since 2022.
Best year ever: 2024, with € 85,204 profit.
On average € 70,500 of value added per employee in 2025.
A new publication or filing at D4-PHARMA? We notify you, reason included.
Follow D4-PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of AGANJU HOLDING comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
D4-PHARMABehind D4-PHARMA is AGANJU HOLDING SRL. The shares are held by AGANJU HOLDING (100%).
Directors
According to the 2025 annual accounts
Director · represented by HAMIAFO NGATCHI HERVE
Also active at: AGANJU CONCEPT, D5-PHARMA, PHARMACIE DES ARCHIDUCS, CENTRE MEDICAL DEWAND, PHARMACIE DU ROOSENDAEL
since 2021
Shareholders
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Legerlaan 7
1040 Etterbeek
Maria Malibranstraat 19
1050 Elsene
Active since 10 February 2017
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0670.945.535
- VAT number
- BE 0670.945.535
- Registered office
- Legerlaan 7, 1040 Etterbeek
- Names & denominations
- D4-PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 10 February 2017
- Peppol
- Active · Active since 11 Dec 2025
- Activities · NACE
Detailhandel in farmaceutische producten